Incyte Says It May Buy Back $30M of Stock | GenomeWeb

NEW YORK, Oct. 14 - Incyte Genomics today said it may spend up to $30 million to buy back its own stock, which it says is undervalued.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.